Ascelia Pharma AB (publ) (ACE) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you and welcome everyone to the webcast for Acelia Pharma's Q2 report for 2025. On this call we will be making a number of forward-looking statements. On today's call we will start with recent key events and then head into our portfolio update before we move to financials and priorities ahead. After the presentation we will open up for questions as usual. At the Senior Pharma, we identify, develop, and commercialize novel drugs that address unmet medical needs within rare cancer conditions. We have two drugs in our pipeline. OrbeGlance is in the registration phase, as we have successfully completed the pivotal phase three clinical study known as SPARQL, and we're preparing the NDA submission, which will be submitted soon. OrbeGlance has orphan drug designation from the FDA and is targeting an addressable market opportunity of $800 million. Oncoral is ready to start phase two clinical development for the treatment of gastric cancer based on encouraging results in phase one and a high level of unmet medical need. Our company is headquartered in Malmö in Sweden and we're listed on Nasdex.com. The second quarter of 2025 was focused on finalizing the Oreglands NDA submission following our meeting with the FDA in Q1. I'd like to briefly mention some of the key highlights. The interest in Orvi glands in the scientific and medical community continues. And in April, we announced acceptance of a poster presentation at the eSport conference about the burden of disease for the Orvi glands target patient population. We also announced an Orvi glands publication in investigative radiology. This publication is a phase two clinical study where we have used a reader evaluation setup similar to the one we've used in our phase three study. where all the glans is evaluated alongsid...